Molecular Medicine Tri-Con Meeting

Irvine, CA — Jan 28, 2020 — ResearchDx will attend the Molecular Medicine Tri-Con Meeting in San Francisco California, March 1–4. Please visit our booth #600, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show. 

Read More

Blood-Based Biomarkers Discriminate IBS from IBD with High Degree of Certainty in Patients with Chronic Diarrhea

Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — July 18, 2019 — ResearchDx will attend the Association of Molecular Pathology (AMP) in Baltimore, Maryland November 7–9, 2019. Please visit our booth #2967, or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.    

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — Oct 1, 2018 — ResearchDx will attend the Association of Molecular Pathology (AMP) in San Antonio, Texas, November 1–3, 2018. Please visit booth #602, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show.

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — November 7, 2017 — ResearchDx will be at the Association for Molecular Pathology (AMP) in Salt Lake City, Utah, November 16-18, 2017. Please visit us at booth 608 or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.

Read More

Finding Needles in the Tumor Haystack: Single Cell HER2 Testing with DEPArray™ NxT Technology

Inside the heterogeneous tumor tissue samples sent to clinical pathology laboratories for HER2 gene testing are cancer genomes with their own inherent complexity. The biopsy (or surgical excision) tissue represents a mixture of genomes from the tumor and normal stroma. Further compounding the heterogeneity problem, tumor genomes harboring HER2 gene amplifications may have amplified HER2 […]

Read More

ResearchDx, Inc. and PacificDx Expand Clinical CLIA Laboratory and Office Space to Accommodate New Research Partners and Assays

Leading contract diagnostics organization has completed construction of a 12,000 square foot addition to their office in Irvine, CA creating a 30,000 square foot headquarters in Irvine, CA. ResearchDx, Inc. announced the completion of a major construction addition to their Orange County headquarters in Irvine California. The company’s building at 5 Mason in Irvine, CA […]

Read More

Guidelines to the Galaxy of HER2 Testing in GEA Cancers

Say the words “HER2 gene amplification” and what immediately comes to mind is breast cancer. But did you know other cancers, including those of the stomach and esophagus (collectively called gastroesophagel adenocarinoma or GEA) can have too many (> 6) copies of the HER2 gene? That’s right, an estimated 20% of GEA cancers harbor an […]

Read More

A Single Blood Test for All Cancers?

What if a simple blood test could detect any cancer early, when it was still easy to treat? It sounds like science fiction. But Illumina ILMN +5.20%, the $24 billion (market cap) biotechnology company that has pioneered cheap, efficient sequencing of DNA, says it could be a reality in a few years. It is launching […]

Read More